戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1   This led to the discovery of a multicystic intraocular tumor.
2 e growth of a highly vascularized angiogenic intraocular tumor.
3 agent on the growth of a highly vascularized intraocular tumor.
4 cedure, PLSU can achieve control of selected intraocular tumors.
5 herapy with sonoporation in the treatment of intraocular tumors.
6  the failure to induce Th17 cells within the intraocular tumors.
7 ated killing of tumor cells and rejection of intraocular tumors.
8  a significant decrease (P = 0.01) in viable intraocular tumors.
9  observed nor necessary for rejection of the intraocular tumors.
10 of CD8+ T cells in the pristine rejection of intraocular tumors.
11 e and prevents the rejection of NK-sensitive intraocular tumors.
12  IFN-gamma knockout mice that fail to reject intraocular tumors, 5) CD4(+) T cells and corneal endoth
13     Retinoblastoma (rb) is the most frequent intraocular tumor, accounting for 3% of all childhood ca
14 role for the TERT/CLPTM1L risk locus in this intraocular tumor and identified multiple highly correla
15 nosis was obtained in 97.6% (n = 121) of the intraocular tumors, and chromosome 3 status could be det
16 diagnostic marker in a select group of adult intraocular tumors, and we highly recommend its inclusio
17 t the Portuguese National Referral Center of Intraocular Tumors, between October 2015 and October 202
18  delivery of paclitaxel effectively inhibits intraocular tumor burden in the LH beta-Tag model of ret
19 nited States are diagnosed as having a large intraocular tumor burden that requires intensive ocular-
20         An enucleation was performed, and an intraocular tumor composed almost entirely of rhabdomyob
21 er eye with intraocular disease) in whom the intraocular tumor did not show (18)F-FDG uptake.
22 her supported by investigations showing that intraocular tumors grew progressively in IFN-gamma KO (k
23               A dose-dependent inhibition of intraocular tumor growth by carboplatin was observed in
24 oplatin in serial doses effectively inhibits intraocular tumor growth in a dose-dependent manner in t
25  chemotherapy agents in a novel setting (ie, intraocular tumor) has been successful in treating all b
26            Uveal melanoma is the most common intraocular tumor in adults and is derived from tissues
27 ccur in uveal melanoma (UM), the most common intraocular tumor in adults.
28       Uveal melanoma (UM) is the most common intraocular tumor in adults.
29  carboplatin safely and effectively controls intraocular tumors in a dose-dependent manner in this mu
30 d studied the methylome in the most frequent intraocular tumors in adults and children (uveal melanom
31 biopsies were performed in 123 patients with intraocular tumors in the posterior segment from January
32 r data indicate that the function of FasL on intraocular tumors is determined by the microenvironment
33  18.7%) were the most common, correlating to intraocular tumor location (P<0.001).
34     However, tumor LBD, tumor thickness, and intraocular tumor location also proved to be significant
35 all had an unequivocal or probable malignant intraocular tumor of a specific type.
36  Retinoblastoma is the most common malignant intraocular tumor of childhood.
37 descriptive analysis of 880 FNABs of a solid intraocular tumor of the posterior ocular segment perfor
38        Of the 41 treatment-naive eyes, a new intraocular tumor (one focus) subsequently developed in
39                                      For all intraocular tumors, optical coherence tomography provide
40 d eyes injected with CD34(+) cells showed no intraocular tumor or abnormal tissue growth after 8 mont
41 redictive of extraocular tumor extension was intraocular tumor recurrence after TTT treated with addi
42 ells circumvent immune privilege and mediate intraocular tumor rejection by a TNF-alpha-dependent man
43 cells from tumor-rejector mice could mediate intraocular tumor rejection following adoptive transfer
44                                              Intraocular tumor rejection required CD4(+) T cells, but
45 se to Ad5E1 tumor Ags or use FasL to mediate intraocular tumor rejection.
46  with TFx, are prospectively correlated with intraocular tumor relapse, response to therapy, and glob
47                                     Although intraocular tumors reside in an immune privileged site,
48                                     Although intraocular tumors reside in an immune-privileged enviro
49                                     Although intraocular tumors reside in an immune-privileged site w
50                                   Conclusion Intraocular tumor size shows a strong association with p
51                Uveal melanoma (UM) is a rare intraocular tumor that, similar to cutaneous melanoma, o
52              Y79 retinoblastoma cells formed intraocular tumors that were initially confined to the v
53  step toward developing an immunotherapy for intraocular tumors, the present study was conducted to e
54 was used as a screening tool to evaluate the intraocular tumor, to evaluate for multi-organ metastati
55                                          The intraocular tumor was detectable in 28% of cases.
56               A dose-dependent inhibition of intraocular tumor was observed after repetitive iontopho
57                                              Intraocular tumor weights were determined on days 10, 14
58                             The sizes of the intraocular tumors were determined.
59 es of transgenic mice that develop pigmented intraocular tumors were produced with the SV40 T and t a
60 lines of transgenic mice developed bilateral intraocular tumors with complete penetrance and without